Stay updated with breaking news from Gavin Xia. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The ODD comes after AP303 presented meaningful improvements in renal survival in an ADPKD and the completion of the first study that evaluated healthy human participants.
Alebund Pharmaceuticals Raises $60 million in Series B Financing Round to Accelerate Its Development of Innovative Drugs and Total Solutions for the Treatment of Renal Diseases News provided by Share this article Share this article SHANGHAI, May 9, 2021 /PRNewswire/ -- Alebund Pharmaceuticals ("Alebund" or the "Company"), a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions, today announced that it has raised $60 million in its Series B financing round which was led by Quan Capital, and followed by a promin...
Alebund Pharmaceuticals, a Shangai, China-based biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions, raised $60m in Series B financing. The round was led by Quan Capital, with participation from 3E Bioventures Capital, and Sherpa Healthcare Partners and existing shareholders Lilly Asia Ventures and Med-Fine Capital. The company intends to use the funds for research and development of pre-clinical assets, clinical programs, the construction of the manufacturing site, and the expansion its talent pool. Fo...